These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2701887)

  • 1. [My career in the outpatient treatment of leprosy].
    Saikawa K
    Nihon Rai Gakkai Zasshi; 1989; 58(3):197-200. PubMed ID: 2701887
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in leprosy control in the last 100 years.
    Bechelli LM
    Int J Lepr Other Mycobact Dis; 1973; 41(3):285-97. PubMed ID: 4591732
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient compliance with dapsone administration in leprosy.
    Huikeshoven H
    Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):228-58. PubMed ID: 7024150
    [No Abstract]   [Full Text] [Related]  

  • 4. A short history of dapsone, or an alternative model of drug development.
    Barr J
    Pharm Hist; 2011; 53(4):123-47. PubMed ID: 24620474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current treatment of leprosy in the Malta pavilion of the Hôpital Saint-Louis].
    Pennec J
    Ann Med Interne (Paris); 1974; 125(6-7):561-4. PubMed ID: 4440971
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prevalence of dapsone-resistant leprosy in Burundi. Temporary results].
    Bourland J; Van Loo L; Pattyn SR
    Acta Leprol; 1982; (86-87):29-33. PubMed ID: 6815995
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of leprosy and immunologic considerations.
    Chatterjee BR
    Lepr India; 1981 Apr; 53(2):142-51. PubMed ID: 7253567
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of secondary dapsone resistance in Gudiyattam Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 1. Preliminary report.
    Balraj V; Jesudasan K; Chacko CJ; Christian M; Taylor PM; Fritschi EP; Job CK
    Int J Lepr Other Mycobact Dis; 1980 Dec; 48(4):397-401. PubMed ID: 7193654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survey on the prevalence rate of dapsone-resistant leprosy in the Yangzhou district].
    Li WZ; Ye GY; Wang HY; Tao MB; Ma B; Zhang YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Feb; 6(1):59-61. PubMed ID: 6238701
    [No Abstract]   [Full Text] [Related]  

  • 10. [Remarks on the epidemiology of leprosy in France in the past 50 years].
    Basset A
    Bull Mem Acad R Med Belg; 1984; 139(2):156-64. PubMed ID: 6386078
    [No Abstract]   [Full Text] [Related]  

  • 11. Present situation of leprosy in Japan, 2006-2010: analysis of drug resistance in new registered and relapsed cases by molecular biological methods.
    Mori S; Yotsu RR; Suzuki K; Makino M; Ishii N
    J Dermatol Sci; 2012 Sep; 67(3):192-4. PubMed ID: 22739027
    [No Abstract]   [Full Text] [Related]  

  • 12. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
    [No Abstract]   [Full Text] [Related]  

  • 13. Leprosy undefeated.
    Browne SG
    Lancet; 1965 Sep; 2(7412):582-3. PubMed ID: 4158202
    [No Abstract]   [Full Text] [Related]  

  • 14. Infectivity of secondary dapsone-resistant cases.
    Jesudasan K; Pannikar V; Christian M
    Int J Lepr Other Mycobact Dis; 1988 Sep; 56(3):418-21. PubMed ID: 3047282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen.
    Kiran KU; Stanley JN; Pearson JM
    Lepr Rev; 1985 Jun; 56(2):127-34. PubMed ID: 4021699
    [No Abstract]   [Full Text] [Related]  

  • 16. Regularity of dapsone intake by leprosy patients attending urban treatment centre.
    Naik SS; Ganapati R
    Lepr India; 1977 Apr; 49(2):207-15. PubMed ID: 909287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary report on a therapeutic trial with acedapsone in lepromatous leprosy.
    Ramanujam K; Iyer CG; Ramu G
    Lepr Rev; 1975 Jun; 46(2 Suppl):85-7. PubMed ID: 1100969
    [No Abstract]   [Full Text] [Related]  

  • 18. The story of sulfones in tropical medicine and dermatology.
    Wozel G
    Int J Dermatol; 1989; 28(1):17-21. PubMed ID: 2645226
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemical drug delivery systems: I. Preparation and evaluation of prodrugs of dapsone.
    Kulkarni VM; Mishra DS
    Indian J Lepr; 1985; 57(4):756-62. PubMed ID: 3835207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic trials in leprosy. 2. Comparative trial of dapsone plus ditophal (Etisul) and dapsone alone in the treatment of lepromatous leprosy.
    Waters MF; Pettit JH
    Int J Lepr; 1965; 33(3):280-96. PubMed ID: 5322767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.